Related Experiment Video

Updated: Oct 10, 2025

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

313

Cannabidiol (CBD) Use among children with juvenile idiopathic arthritis

Christopher J Failing1,2,3, Kevin F Boehnke4,5, Meredith Riebschleger6,7

  • 1Department of Pediatric Rheumatology, C.S. Mott Children's Hospital, Ann Arbor, United States, MI. chris.failing@gmail.com.

Pediatric Rheumatology Online Journal
|December 14, 2021
PubMed

Insights

Caregivers of children with juvenile idiopathic arthritis (JIA) show interest in cannabidiol (CBD) despite infrequent use. More research and education are needed regarding CBD safety and efficacy for JIA management.

Area of Science:

  • Pediatric Rheumatology
  • Cannabinoid Therapeutics
  • Patient Caregiver Attitudes

Background:

  • Juvenile idiopathic arthritis (JIA) presents significant treatment challenges.
  • Cannabidiol (CBD) is increasingly accessible, yet its application in JIA remains unstudied.
  • Caregiver perspectives on CBD for JIA are largely unknown.

Purpose of the Study:

  • To investigate caregiver knowledge, attitudes, and interest in using cannabidiol (CBD) for juvenile idiopathic arthritis (JIA).
  • To assess current CBD usage patterns and information sources among caregivers of JIA patients.
  • To identify gaps in communication between caregivers and healthcare providers regarding CBD for JIA.

Main Methods:

  • Retrospective chart review of JIA patients (2017-2019) at a Midwestern institution.
  • Anonymous online survey distributed to primary caregivers of JIA patients.
  • Descriptive statistical analysis comparing caregivers with varying levels of interest in CBD.

Main Results:

  • Of 136 surveyed caregivers, 34.5% expressed no interest in CBD, while 54% contemplated and 7% currently used CBD for their child's JIA.
  • Information on CBD primarily came from television (70%) or friends (50%), not rheumatologists (2%).
  • Most caregivers had not discussed CBD with their child's rheumatologist; current users often lacked knowledge of CBD dosage.

Conclusions:

  • A significant caregiver interest in CBD for JIA exists, contrasting with current low usage rates.
  • The lack of rheumatologist involvement and limited caregiver knowledge highlight a critical need for improved education.
  • Further research into the safety and efficacy of CBD for pediatric JIA is warranted.
Abstract

Keywords:
CannabidiolComplementary and integrative medicineJuvenile idiopathic arthritisPediatric rheumatology

More Related Videos

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies05:25

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

2.7K
Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass05:46

Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass

Published on: May 27, 2022

6.4K

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
411
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
284
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
32
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
236
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
256
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
18